|
시장보고서
상품코드
2039053
혈장 프로테아제 C1 억제제 치료 시장 : 약제 유형별, 제형별, 유통 채널별, 지역별Plasma Protease C1-inhibitor Treatment Market, By Drug Type, By Dosage, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
혈장 프로테아제 C1 억제제 치료 시장은 2026년에 43억 8,000만 달러로 추정되며, 2033년까지 80억 6,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR은 9.1%를 보일 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 43억 8,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 9.10% | 예측 금액(2033년) | 80억 6,000만 달러 |
C1 억제제(C1-H)는 세린 프로테아제 억제제 슈퍼패밀리에 속합니다. C1 억제제는 C1 복합체의 활성화를 조절합니다. C1r 또는 C1s 프로테아제와 단백질 분해 활성이 없는 화학량론적 복합체를 형성합니다. 또한 보체 활성화, 혈액 응고, 섬유소 용해, 키닌 생성 등 중요한 생리학적 경로의 조절에도 중요한 역할을 합니다. FXIIa 인자의 가장 효율적인 억제제이며, 키모트립신과 칼리클레인을 억제합니다.
시장 역학
유전성 혈관성 부종(HAE)은 C1 에스테라아제 억제인자 결핍이 특징인 질환입니다. 2013년 미국 국립생물공학정보센터(NCBI)가 보고한 자료에 따르면, 일반 인구에서 HAE의 추정 유병률은 전 세계적으로 1만 명당 1명에서 15만 명당 1명의 범위에 속합니다. 의약품 등급의 C1 억제제인 신라이즈(Cinryze)는 2008년 미국 식품의약국(FDA)으로부터 HAE 치료제로 승인받았습니다. 신라이즈는 고도로 정제되고 저온 살균 및 나노 여과 처리된 혈장 유래 C1 에스테라아제 억제제 제품으로, HAE를 앓고 있는 청소년 및 성인 환자의 혈관부종 발작에 대한 정기적인 예방 요법으로 승인되었습니다. 따라서 HAE 치료에서 혈장 유래 C1 에스 테라제 억제제 제품의 사용 증가 추세가 세계 혈장 프로테아제 C1 억제제 치료제 시장의 성장을 견인할 것으로 예측됩니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 혈장 프로테아제 C1 억제제 치료제 시장의 주요 기업 프로파일을 다양한 매개변수(기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등)에 따라 정리하여 전해드립니다.
- 세계 혈장 프로테아제 C1 억제제 치료제 시장에서 활동하는 주요 기업으로는 CSL Behring LLC, Takeda Pharmaceuticals, Ionis Pharmaceuticals, Inc. BioCryst Pharmaceuticals, 그리고 KalVista Pharmaceuticals, Inc.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 혈장 프로테아제 C1 억제제 치료 시장' 보고서는 투자자, 공급업체, 제약업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 혈장 프로테아제 C1 억제제 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 혈장 프로테아제 C1 억제제 치료 시장 : 약제 유형별(2021년-2033년)
제5장 세계의 혈장 프로테아제 C1 억제제 치료 시장 : 제형별(2021년-2033년)
제6장 세계의 혈장 프로테아제 C1 억제제 치료 시장 : 유통 채널별(2021년-2033년)
제7장 세계의 혈장 프로테아제 C1 억제제 치료 시장 : 지역별(2021년-2033년)
제8장 경쟁 구도
제9장 섹션
LSH 26.06.04Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at USD 4.38 Bn in 2026 and is expected to reach USD 8.06 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.38 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.10% | 2033 Value Projection: | USD 8.06 Bn |
C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.
Market Dynamics
Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.
Plasma Protease C1-inhibitor Treatment Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- C1-inhibitors
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- By Dosage (Revenue, USD Bn, 2021-2033)
- Lyophilized
- Injectable
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Plasma Protease C1-inhibitor Treatment Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- CSL Behring LLC
- Takeda Pharmaceutical Company Limited
- Ionis Pharmaceuticals, Inc.
- Pharming Technologies B.V.
- Centogene AG
- BioCryst Pharmaceuticals
- KalVista Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Dosage
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- C1-inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Selective Bradykinin B2 Receptor Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Lyophilized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Plasma Protease C1-inhibitor Treatment Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- CSL Behring LLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Ionis Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pharming Technologies B.V.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Centogene AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- BioCryst Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- KalVista Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
